Trial Profile
Rivastigmine (Exelon) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Dementia
- Focus Therapeutic Use
- 05 Sep 2007 New trial record.